Business Context and Reporting Period
This Form 8-K is a current report filed by Novus Therapeutics, Inc. (not Eledon Pharmaceuticals, Inc.) on September 4, 2020, regarding events occurring on September 3, 2020. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol NVUS.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
- CEO Resignation: Gregory Flesher resigned as Chief Executive Officer and Board member, effective September 4, 2020. The resignation is not the result of any dispute with the company.
- Consulting Agreement: Mr. Flesher will provide consulting and transition-support services at an hourly rate consistent with his target compensation.
- Interim Appointment: Jon Kuwahara, previously Senior Vice President of Finance & Administration and Principal Financial Officer, was appointed as Interim Principal Executive Officer effective September 4, 2020.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future operations. No specific risks or contingencies related to the leadership change were disclosed beyond the standard statement that the departure was not due to a dispute.
Investor Verification Checklist
- Verify the exact terms and duration of the consulting agreement with the departing CEO.
- Confirm the timeline for a permanent CEO search and appointment.
- Review the company's most recent Proxy Statement for full biographical details on the interim CEO, Jon Kuwahara.
- Monitor subsequent filings for any impact on the company's strategic direction or clinical development pipeline.